Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
20,707
archived clinical trials in
Gastrointestinal

Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Gastro-Enterology Research of Lima
mi
from
Lima, OH
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Gastro-Enterology Research of Lima
mi
from
Lima, OH
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Options Health Research
mi
from
Tulsa, OK
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Options Health Research
mi
from
Tulsa, OK
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
San Antonio Gastroenterology
mi
from
San Antonio, TX
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
San Antonio Gastroenterology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Allegiance Research Specialists, LLC
mi
from
Milwaukee, WI
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Allegiance Research Specialists, LLC
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Arizona Arthritis & Rheumatology Research PLLC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Gastroenterology Center of the Midsouth
mi
from
Germantown, TN
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Gastroenterology Center of the Midsouth
mi
from
Germantown, TN
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Grand Teton Research Group, PLL
mi
from
Idaho Falls, ID
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Grand Teton Research Group, PLL
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated:  12/31/1969
Concord Repatriation General Hospital
mi
from
Concord,
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's Disease
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Vedolizumab Subcutaneous as Maintenance Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Status: Enrolling
Updated: 12/31/1969
Concord Repatriation General Hospital
mi
from
Concord,
Click here to add this to my saved trials
Randomized Controlled Trial of Social Network Targeting in Honduras
Randomized Controlled Trial of Social Network Targeting to Magnify Population-Level MNCH Behavior Change in Honduras
Status: Enrolling
Updated:  12/31/1969
Yale Institute for Network Science
mi
from
New Haven, CT
Randomized Controlled Trial of Social Network Targeting in Honduras
Randomized Controlled Trial of Social Network Targeting to Magnify Population-Level MNCH Behavior Change in Honduras
Status: Enrolling
Updated: 12/31/1969
Yale Institute for Network Science
mi
from
New Haven, CT
Click here to add this to my saved trials
Randomized Controlled Trial of Social Network Targeting in Honduras
Randomized Controlled Trial of Social Network Targeting to Magnify Population-Level MNCH Behavior Change in Honduras
Status: Enrolling
Updated:  12/31/1969
Community intervention
mi
from
Copan Ruinas,
Randomized Controlled Trial of Social Network Targeting in Honduras
Randomized Controlled Trial of Social Network Targeting to Magnify Population-Level MNCH Behavior Change in Honduras
Status: Enrolling
Updated: 12/31/1969
Community intervention
mi
from
Copan Ruinas,
Click here to add this to my saved trials
[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT
Status: Enrolling
Updated:  12/31/1969
VA Palo Alto Healthcare System
mi
from
Palo Alto, CA
[18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer
Assessment of Treatment-Induced Tissue Hypoxia After Transcatheter Arterial Embolization of Hepatocellular Carcinoma: A Feasibility Study With [18F]FMISO PET/CT
Status: Enrolling
Updated: 12/31/1969
VA Palo Alto Healthcare System
mi
from
Palo Alto, CA
Click here to add this to my saved trials
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
Transarterial Embolization and Microwave Ablation Combination Therapy in Early-stage Hepatocellular Carcinoma: A Randomized Trial
Status: Enrolling
Updated:  12/31/1969
Carolinas Medical Center
mi
from
Charlotte, NC
TAE and MWA Combination Therapy in Early-stage Hepatocellular Carcinoma
Transarterial Embolization and Microwave Ablation Combination Therapy in Early-stage Hepatocellular Carcinoma: A Randomized Trial
Status: Enrolling
Updated: 12/31/1969
Carolinas Medical Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 112
mi
from
San Clemente, CA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 112
mi
from
San Clemente, CA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 101
mi
from
Detroit, MI
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 101
mi
from
Detroit, MI
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 102
mi
from
Kansas City, MO
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 102
mi
from
Kansas City, MO
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 910
mi
from
Dallas, TX
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 910
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 101
mi
from
Norfolk, VA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 101
mi
from
Norfolk, VA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 118
mi
from
Sacramento, CA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 118
mi
from
Sacramento, CA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 127
mi
from
San Francisco, CA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 127
mi
from
San Francisco, CA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 106
mi
from
Aurora, CO
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 106
mi
from
Aurora, CO
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 110
mi
from
Gainesville, FL
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 110
mi
from
Gainesville, FL
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 124
mi
from
Lakewood Ranch, FL
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 124
mi
from
Lakewood Ranch, FL
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 105
mi
from
Miami, FL
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 105
mi
from
Miami, FL
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 109
mi
from
Indianapolis, IN
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 109
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 107
mi
from
Saint Louis, MO
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 107
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 103
mi
from
New York, NY
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 103
mi
from
New York, NY
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 903
mi
from
Durham, NC
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 903
mi
from
Durham, NC
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 120
mi
from
Cincinnati, OH
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 120
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 114
mi
from
Nashville, TN
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 114
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 119
mi
from
Houston, TX
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 119
mi
from
Houston, TX
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 125
mi
from
Southlake, TX
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 125
mi
from
Southlake, TX
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 904
mi
from
Charlottesville, VA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 904
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 912
mi
from
Newport News, VA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 912
mi
from
Newport News, VA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 911
mi
from
Richmond, VA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 911
mi
from
Richmond, VA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 908
mi
from
Seattle, WA
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 908
mi
from
Seattle, WA
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 301
mi
from
Paris,
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 301
mi
from
Paris,
Click here to add this to my saved trials
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated:  12/31/1969
NGM Clinical Study Site 115
mi
from
Washington,
Phase 2 Study of NGM282 in Patients With Primary Sclerosing Cholangitis
A Phase 2, Randomized, Double Blind, Placebo Controlled, Parallel Group, Multiple Center Study to Evaluate the Safety, Tolerability, and Efficacy of NGM282 Administered for 12 Weeks in Patients With Primary Sclerosing Cholangitis
Status: Enrolling
Updated: 12/31/1969
NGM Clinical Study Site 115
mi
from
Washington,
Click here to add this to my saved trials
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Treatment of IgG4-Related Disease With Revlimid and Rituximab
Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
a4b7 Integrin in Eosinophilic Esophagitis
Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
a4b7 Integrin in Eosinophilic Esophagitis
Investigating the Role of a4b7 Integrin as a Therapeutic Target in Eosinophilic Esophagitis
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Minocycline Administration During Human Liver Transplantation
Minocycline Administration During Human Liver Transplantation
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Minocycline Administration During Human Liver Transplantation
Minocycline Administration During Human Liver Transplantation
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rochester, MN
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rochester, MN
Click here to add this to my saved trials
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Harrow,
To Assess Safety, Tolerability and Efficacy of LJN452 in Patients With Primary Bile Acid Diarrhea.
A Double Blind, Randomized Placebo Controlled Crossover Multiple Dose Study of LJN452 to Assess Safety, Tolerability and Efficacy in Patients With Primary Bile Acid Diarrhea (pBAD).
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Harrow,
Click here to add this to my saved trials
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Status: Enrolling
Updated:  12/31/1969
Cornell Medical Center
mi
from
New York, NY
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Status: Enrolling
Updated: 12/31/1969
Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Status: Enrolling
Updated:  12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Status: Enrolling
Updated: 12/31/1969
U.T. Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence
Status: Enrolling
Updated:  12/31/1969
The APT Foundation
mi
from
New Haven, CT
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence
A Naturalistic Study of Adolescents and Young Adults in Treatment for Opioid Dependence
Status: Enrolling
Updated: 12/31/1969
The APT Foundation
mi
from
New Haven, CT
Click here to add this to my saved trials
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX. A Humanitarian Use Device ( HUD), Which Has Recently Received a Humanitarian Device Exemption (HDE) From the Food and Drug Administration ( FDA)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX. A Humanitarian Use Device ( HUD), Which Has Recently Received a Humanitarian Device Exemption (HDE) From the Food and Drug Administration ( FDA)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX. A Humanitarian Use Device ( HUD), Which Has Recently Received a Humanitarian Device Exemption (HDE) From the Food and Drug Administration ( FDA)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX
Clinical Use of a Magnetic Anal Sphincter Augmentation Device, Trade Name FENIX. A Humanitarian Use Device ( HUD), Which Has Recently Received a Humanitarian Device Exemption (HDE) From the Food and Drug Administration ( FDA)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
A Study of the Safety and Efficacy of Teduglutide in Subjects With Parenteral Nutrition-Dependent Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic Scottsdale
mi
from
Scottsdale, AZ
Click here to add this to my saved trials